Stryker Co. (SYK) Given Average Recommendation of “Hold” by Brokerages

Shares of Stryker Co. (NYSE:SYK) have been given an average rating of “Hold” by the twenty-five brokerages that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have given a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $161.72.

Several research analysts have recently commented on SYK shares. Wells Fargo & Co raised their price target on Stryker from $160.00 to $166.00 in a research report on Friday, October 27th. SunTrust Banks restated a “buy” rating and set a $161.00 price target on shares of Stryker in a research report on Friday, November 17th. Cowen set a $166.00 price target on Stryker and gave the stock a “buy” rating in a research report on Sunday, October 29th. ValuEngine upgraded Stryker from a “hold” rating to a “buy” rating in a research report on Tuesday, November 14th. Finally, Canaccord Genuity raised their price target on Stryker from $155.00 to $162.00 and gave the stock a “buy” rating in a research report on Friday, October 27th.

In other Stryker news, insider Graham A. Mclean sold 2,984 shares of the firm’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $160.53, for a total value of $479,021.52. Following the sale, the insider now directly owns 9,100 shares in the company, valued at $1,460,823. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP William E. Berry, Jr. sold 1,306 shares of the firm’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $164.42, for a total value of $214,732.52. The disclosure for this sale can be found here. Over the last quarter, insiders sold 16,840 shares of company stock worth $2,749,989. Insiders own 7.40% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the business. Chemical Bank raised its stake in Stryker by 24.1% in the fourth quarter. Chemical Bank now owns 12,936 shares of the medical technology company’s stock valued at $2,003,000 after buying an additional 2,515 shares in the last quarter. Green Square Capital LLC raised its stake in Stryker by 148.5% in the fourth quarter. Green Square Capital LLC now owns 5,606 shares of the medical technology company’s stock valued at $871,000 after buying an additional 3,350 shares in the last quarter. Rehmann Capital Advisory Group raised its stake in Stryker by 7.8% in the fourth quarter. Rehmann Capital Advisory Group now owns 5,306 shares of the medical technology company’s stock valued at $822,000 after buying an additional 385 shares in the last quarter. Colonial Trust Advisors raised its stake in Stryker by 40.9% in the fourth quarter. Colonial Trust Advisors now owns 33,883 shares of the medical technology company’s stock valued at $5,246,000 after buying an additional 9,836 shares in the last quarter. Finally, Xact Kapitalforvaltning AB increased its position in shares of Stryker by 7.3% during the fourth quarter. Xact Kapitalforvaltning AB now owns 57,539 shares of the medical technology company’s stock worth $8,909,000 after purchasing an additional 3,912 shares in the last quarter. Institutional investors own 74.49% of the company’s stock.

Shares of Stryker (NYSE SYK) traded up $2.74 during trading on Friday, reaching $161.70. The company had a trading volume of 983,059 shares, compared to its average volume of 1,470,000. The stock has a market capitalization of $60,580.00, a price-to-earnings ratio of 33.00, a price-to-earnings-growth ratio of 2.29 and a beta of 0.70. Stryker has a 52 week low of $127.19 and a 52 week high of $170.00. The company has a quick ratio of 1.59, a current ratio of 2.29 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 EPS for the quarter, topping the consensus estimate of $1.95 by $0.01. Stryker had a return on equity of 24.56% and a net margin of 8.20%. The business had revenue of $3.47 billion during the quarter, compared to analyst estimates of $3.42 billion. During the same period last year, the business posted $1.78 earnings per share. The company’s quarterly revenue was up 9.9% on a year-over-year basis. equities research analysts predict that Stryker will post 7.12 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 1.16%. The ex-dividend date of this dividend is Wednesday, March 28th. Stryker’s payout ratio is currently 38.37%.

COPYRIGHT VIOLATION WARNING: “Stryker Co. (SYK) Given Average Recommendation of “Hold” by Brokerages” was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.thelincolnianonline.com/2018/02/24/stryker-co-syk-given-average-recommendation-of-hold-by-brokerages.html.

Stryker Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Analyst Recommendations for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply